
    
      This is a Phase 2a, randomised, double-blind study in 300 adults to compare the safety and
      immunogenicity of OVX836 to QIV (Influvac TetraTM). One dose of OVX836 at two dose levels
      will be administered intramuscularly, in comparison to Influvac TetraTM, quadrivalent
      seasonal influenza sub-unit vaccine in healthy subjects aged 18-65 years.
    
  